About
CancerGuide Diagnostics, founded in 2006, is a life science company, focused on the development and commercialization of genomic-based clinical and pharmaceutical cancer tests and services, enabling physicians, patients, and drug developers to make individualized treatment or drug discovery decisions.
CancerGuide Diagnostics was founded and launched by experienced professionals in the commercial diagnostic, cancer, and genomic space. We are passionate about fulfilling the unmet needs in current cancer care and drug development.
Our Mission
Enhance the treatment and survival of cancer patients through the efficient and quality-focused development of cutting-edge diagnostic and therapeutic discoveries
Effectively partner with pharmaceutical and biotech organizations, IVD manufacturers, managed care organizations, regulatory agencies, advocacy groups, academic institutions, and commercial laboratories to make personalized cancer treatment a reality
Offer actionable individualized treatment decision tools and approaches for practicing oncologists, pathologists, and drug developers
Why we are different?
While the value of personalized medicine to drug developers, clinicians, and patients may be increasingly discussed, the pace at which it will transform healthcare is uncertain.
The complexity of integrating scientific, regulatory, economic, educational, and policy issues can impede product development, clinical acceptance, and lead to slow adoption of worthwhile new approaches to cancer treatment. CancerGuide combines unique technical capability with exceptional diagnostic leadership to breakdown the traditional bottlenecks caused by these issues.
Most commercialization efforts focused on new personalized medicine discoveries, lack the required resources, leadership, and infrastructure necessary to efficiently advance them into clinical use.